Multimodality therapy, such as a combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), is associated with improved survival for selected patients with peritoneal metastasis of various cancer types. Despite this, this procedure is not widely accepted due to its high rates of morbidity and mortality. In several studies on the combined use of CRS and HIPEC to treat patients with a variety of cancer types, the rates of grade III/IV morbidity and mortality ranged from 22% to 34% and from 0.8% to 4.1%, respectively. Common major postoperative complications included neutropenia, anastomotic leakage, pneumonia, postoperative bleeding, intra-abdominal abscess, systemic sepsis, wound infection, pleural effusion, and renal insufficiency [1] . Kim et al. [2] reported 30-day rates of postoperative morbidity and mortality of 30.4% and 0%, respectively, which are comparable to the results reported in Newton et al. [1] and Jo et al. [3] . The occurrence of major complications was found to be associated with the number of organ resections (more than 3), the duration of surgery (≥630 minutes) and the amount of blood loss (≥600 mL) during surgery. However, contrary to other reports, all four patients with recurred colorectal cancer treated with cetuximab had grade III postoperative complications [2] .
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Recently, we reported the results of a 2-year follow-up at our center. The rate of morbidity above grade III was 22.2%. Pulmonary complications, such as pleural effusion and pneumonia, were the most common (29.6%) complications, followed by acute renal failure (14.8%), wound problems (13.0%), and prolonged ileus (11.1%). Anastomotic leakage developed in 1 patient. The rate of mortality was 7.4%. The causes of death included pulmonary complication, septic shock related to anastomotic leakage, and hypovolemic shock from gastrointestinal bleeding [3] .
According to data from the National Surgical Quality Improvement Program (NSQIP), age ≥ 60 years, preoperative albumin < 3 g/dL, and poor preoperative performance status are major factors contributing to morbidity [4] . Major operative factors are the peritoneal cancer index, bowel resection, diaphragmatic involvement [5] , the use of a distal pancreatectomy, and surgeon's experience. Furthermore, hepatobiliary procedures, urologic procedures, and preoperative use of bevacizumab have weak associations with the occurrence of morbidity. In a NSQIP analysis, increased operative time, intraoperative transfusion, and the use of a gastrectomy with intraperitoneal chemotherapy were associated with increased morbidity and mortality [4] . Studies suggest that perioperative systemic chemotherapy does not appear to increase the rate of major morbidities from the use of a combined CRS and HIPEC procedure, with the possible exception of preoperative bevacizumab, which has been associated with increased operative complications. Intraperitoneal chemotherapy increases neither morbidity nor mortality greatly over surgery alone [4] .
One of the major limitations of this study [2] is that the number of patients treated with the combined CRS and HIPEC procedure was small (n = 23). Some studies suggest that approximately 140-180 procedures are needed to minimize severe morbidity [6] , but in this paper, even though the number of patients was small, the rate of morbidity was comparable to the value in a report published by a large-volume center. This suggests that the combined use of CRS and HIPEC will become a somewhat popular procedure, in spite of its being a complex procedure. The combined use of CRS and HIPEC to treat patients with disseminated intra-abdominal malignancies is a complex procedure with the potential for high morbidity and mortality. However, when the combined CRS and HIPEC procedure is performed by experienced sur-
